A new class of drugs for systolic heart failure: The PARADIGM-HF study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 26469827.
- Also identified by DOI 10.3949/ccjm.82a.14163.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
Medical subject headings
- Aminobutyrates
- Angiotensin Receptor Antagonists
- Heart Failure, Systolic
- Neprilysin
- Tetrazoles